ALLOGENE THERAPEUTICS INC (ALLO) Earnings History & Surprises
NASDAQ:ALLO • US0197701065
2.5 USD
+0.2 (+8.7%)
At close: Mar 9, 2026
2.53 USD
+0.03 (+1.2%)
Pre-Market: 3/10/2026, 7:00:00 AM
Past quarterly earnings results for ALLOGENE THERAPEUTICS INC (ALLO), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Release DateMar 12, 2026
PeriodQ4 / 2025
EPS Estimate-$0.22
Revenue Estimate
Last Reported
Release DateNov 6, 2025
PeriodQ3 / 2025
EPS Reported-$0.19
EPS Surprise 16.55%
Revenue Surprise %
Beat Rate
50%
EPS and Revenuebeats vs estimates
Quarterly Earnings Results
EPS & Revenue History (USD)
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.19 | -0.23 | 16.55% | 40.63% | - | - | ||
| Q2 2025 | -0.23 | -0.28 | 17.55% | 34.29% | 1.856K | -100.00% | - | |
| Q1 2025 | -0.28 | -0.30 | 5.26% | 26.32% | 1.856K | -100.00% | -100.00% | |
| Q4 2024 | -0.28 | -0.34 | 17.64% | 34.88% | 14.28K | -100.00% | -100.00% | |
| Q3 2024 | -0.32 | -0.34 | 4.75% | 13.51% | 13.189K | -100.00% | -100.00% | |
| Q2 2024 | -0.35 | -0.35 | 1.21% | 33.96% | 17.248K | -100.00% | -100.00% | |
| Q1 2024 | -0.38 | -0.42 | 8.99% | 44.12% | 22K | 9.792K | 124.67% | -57.69% |
| Q4 2023 | -0.43 | -0.46 | 6.14% | 34.85% | 21K | 24.041K | -12.65% | -58.00% |
| Q3 2023 | -0.37 | -0.53 | 30.17% | 36.21% | 43K | 12.781K | 236.45% | -14.00% |
| Q2 2023 | -0.53 | -0.60 | 11.77% | -1.92% | 44K | 19.268K | 128.36% | -51.11% |
| Q1 2023 | -0.68 | -0.63 | -8.03% | -21.43% | 52K | 10.914K | 376.45% | -13.33% |
| Q4 2022 | -0.66 | -0.71 | 7.43% | -22.22% | 50K | 61.404K | -18.57% | - |
| Q3 2022 | -0.58 | -0.66 | 11.76% | -1.75% | 50K | 14.912K | 235.29% | - |
| Q2 2022 | -0.52 | -0.62 | 16.43% | 1.89% | 90K | 5.661K | 1,489.83% | 125.00% |
| Q1 2022 | -0.56 | -0.59 | 4.62% | -124.00% | 60K | - | -99.84% | |
| Q4 2021 | -0.54 | -0.61 | 11.52% | -1.89% | 50K | -6.324K | 890.64% | - |
| Q3 2021 | -0.57 | -0.57 | 0.01% | -9.62% | 50K | 14.576K | 243.03% | - |
| Q2 2021 | -0.53 | -0.56 | 4.97% | - | 40K | 235.814K | -83.04% | - |
| Q1 2021 | -0.25 | -0.46 | 46.19% | 50.00% | 38.35M | 13.102M | 192.70% | - |
| Q4 2020 | -0.53 | -0.57 | 6.80% | - | 3.23M | -100.00% | - | |
| Q3 2020 | -0.52 | -0.55 | 5.21% | - | - | - | ||
| Q2 2020 | -0.53 | -0.55 | 4.01% | - | - | - | ||
| Q1 2020 | -0.50 | -0.59 | 15.10% | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
4
Average EPS beat (4)
14.25%
Max EPS beat (4)
17.64%
Min EPS beat (4)
5.26%
Revenue beat statistics
Revenue beat (4)
N/A
Average Revenue beat (4)
N/A
Max Revenue beat (4)
N/A
Min Revenue beat (4)
N/A
Analysis
In the last 4 quarters, ALLO has consistently beaten EPS estimates in all releases
In the last 4 quarters, ALLO has beaten the EPS estimates by 14.3% on average.
ALLOGENE THERAPEUTICS INC / ALLO Earnings FAQ
What is the most recent earnings date for ALLO stock?
ALLOGENE THERAPEUTICS INC (ALLO) last reported earnings on 11/6/2025.
Did ALLOGENE THERAPEUTICS INC (ALLO) beat earnings estimates last quarter?
ALLOGENE THERAPEUTICS INC (ALLO) beat EPS estimates and missed revenue estimates in the most recent quarter.
Can you provide information on how often ALLOGENE THERAPEUTICS INC beats earnings estimates?
In the last 4 quarters, ALLOGENE THERAPEUTICS INC (ALLO) has beaten EPS estimates in 4 out of 4 releases.